[go: up one dir, main page]

AU2001232348A1 - Sustained release preparations of physiologically active compound hardly solublein water and production process and use of the same - Google Patents

Sustained release preparations of physiologically active compound hardly solublein water and production process and use of the same

Info

Publication number
AU2001232348A1
AU2001232348A1 AU2001232348A AU3234801A AU2001232348A1 AU 2001232348 A1 AU2001232348 A1 AU 2001232348A1 AU 2001232348 A AU2001232348 A AU 2001232348A AU 3234801 A AU3234801 A AU 3234801A AU 2001232348 A1 AU2001232348 A1 AU 2001232348A1
Authority
AU
Australia
Prior art keywords
production process
active compound
same
sustained release
physiologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001232348A
Inventor
Yasutaka Igari
Shigeru Kamei
Takahito Kitayoshi
Mami Ojima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AU2001232348A1 publication Critical patent/AU2001232348A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001232348A 2000-02-21 2001-02-20 Sustained release preparations of physiologically active compound hardly solublein water and production process and use of the same Abandoned AU2001232348A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000048980 2000-02-21
JP2000-048980 2000-02-21
PCT/JP2001/001191 WO2001060410A1 (en) 2000-02-21 2001-02-20 Sustained release preparations of physiologically active compound hardly soluble in water and production process and use of the same

Publications (1)

Publication Number Publication Date
AU2001232348A1 true AU2001232348A1 (en) 2001-08-27

Family

ID=18570981

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001232348A Abandoned AU2001232348A1 (en) 2000-02-21 2001-02-20 Sustained release preparations of physiologically active compound hardly solublein water and production process and use of the same

Country Status (5)

Country Link
US (1) US20030068374A1 (en)
EP (1) EP1258254A4 (en)
AU (1) AU2001232348A1 (en)
CA (1) CA2400845A1 (en)
WO (1) WO2001060410A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2426674A1 (en) * 2000-10-25 2002-05-02 Takeda Chemical Industries, Ltd. Agent for preventing or treating portal hypertension
US20040121008A1 (en) * 2001-03-16 2004-06-24 Keiko Shiraishi Process for producing sustained release preparation
WO2003041739A1 (en) 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Anticaner agents
MY131170A (en) * 2002-03-28 2007-07-31 Nissan Chemical Ind Ltd Therapeutic agent for glomerular disease
ATE551056T1 (en) * 2002-12-27 2012-04-15 Takeda Pharmaceutical AGENT FOR INHIBITING BODY WEIGHT GAIN
US20050220881A1 (en) * 2003-10-10 2005-10-06 Bvm Holding Co. Pharmaceutical composition
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
FR2882260A1 (en) * 2005-02-21 2006-08-25 Flamel Technologies Sa MULTIMICROPARTICULAR ORAL PHARMACEUTICAL FORM WITH MODIFIED RELEASE OF ANTAGONISTS OF ANGIOTENSIN II RECEPTORS
DE602006008962D1 (en) * 2005-08-22 2010-07-08 Alembic Ltd PROCESS FOR PREPARING VALSARTAN
EP1897537A1 (en) * 2006-09-04 2008-03-12 Novartis AG Composition comprising an angiotensin II receptor antagonist
PE20081364A1 (en) * 2006-09-04 2008-12-04 Novartis Ag PHARMACEUTICAL COMPOSITION INCLUDING VALSARTAN
CN101677961B (en) * 2007-03-28 2012-10-17 武田药品工业株式会社 Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a ph control agent
CN101730467A (en) * 2007-07-06 2010-06-09 努恩治疗学股份有限公司 Treatment of neuropathic pain
MX2011001150A (en) 2008-07-31 2011-03-29 Takeda Pharmaceutical Solid pharmaceutical composition.
JP6830892B2 (en) 2014-12-05 2021-02-17 アラゴン ファーマシューティカルズ，インコーポレイテッド Anti-cancer composition
CN114886852A (en) 2014-12-05 2022-08-12 阿拉贡药品公司 Anticancer composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69519382T3 (en) * 1994-09-09 2008-09-18 Takeda Pharmaceutical Co. Ltd. PREPARATION WITH DELAYED RELEASE OF A METAL SALT OF A PEPTIDE
WO1997001331A2 (en) * 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
KR20010086245A (en) * 1998-03-04 2001-09-10 다케다 야쿠힌 고교 가부시키가이샤 Sustained-release preparation for aⅱ antagonist, production and use thereof

Also Published As

Publication number Publication date
CA2400845A1 (en) 2001-08-23
EP1258254A1 (en) 2002-11-20
EP1258254A4 (en) 2004-02-04
WO2001060410A1 (en) 2001-08-23
US20030068374A1 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
AU2000260550A1 (en) Treatment of skin damage using polyenylphosphatidylcholine
AU2002235140A1 (en) Fluidic self-assembly of active antenna
AU2001232348A1 (en) Sustained release preparations of physiologically active compound hardly solublein water and production process and use of the same
AU2001229712A1 (en) Reduction of hair growth
HUP0300527A3 (en) Pyrrolopyrimidinone derivatives, process of preparation and use
AU2001282267A1 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
AU2002335046A1 (en) The use of proton sequestering agents in drug formulations
AU2001269046A1 (en) Use of therapeutic benzamide derivatives
AU2001270778A1 (en) Production, stabilisation and use of reduced forms of pharmaceutical compounds
AU2001265253A1 (en) Treatment of hiv using hyperthermia
AU3622600A (en) Metalloproteinases and methods of use therefor
AU5428700A (en) Acrylic acid derivatives, use of the same and intermediates for the preparation thereof
AU2001234089A1 (en) Cancer remedy comprising anthranilic acid derivative as active ingredient
AU7958100A (en) Crystals of an oxyiminoalkanoic acid derivative and their use as antidiabetics
AU2001284763A1 (en) Preparation of risperidone
AU2982000A (en) Preparation of 9-hydrocarbyl-9-phosphabicyclononanes
HUP0302310A3 (en) Novel formulations of alpha-2,4-disulfophenyl-n-tert-butylnitrone and process for their preparation
AU2001241771A1 (en) Use of avocado-soybean unsaponifiable preparations
AU2001265280A1 (en) Preparation of 2-hydroxy-5-oxoproline and analogs thereof
AU2001264863A1 (en) Preparation of fagopyritols and uses therefor
AU2002212281A1 (en) Anti-inflammatory active ingredients
AU3775500A (en) Setting of gemstones
AU2662900A (en) One-pot process for the preparation of 5-sulfonyl-substituted benzotriazoles
AU2001245950A1 (en) Preparation of deoxynucleosides
AU2001220267A1 (en) Novel 1beta-methylcarbapenem derivatives and process of preparation thereof